| Similar Articles |
|---|
 |
The Motley Fool
February 1, 2008
Brian Lawler |
Alexion Looks for a Bigger Niche Alexion Pharmaceutical announces sales of its rare blood disorder medication should expand in 2008.   |
The Motley Fool
April 30, 2007
Brian Lawler |
Alexion Heads Overseas Alexion is headed for approval of its lead compound in the European Union. With no other compounds in clinical stage development, an investment in Alexion is all about the market potential for Soliris. |
The Motley Fool
July 21, 2011
Tim Beyers |
Alexion Pharmaceuticals Shares Popped: What You Need to Know Shares of Alexion Pharmaceuticals rose close to 11% in early trading and touched a new 52-week high of $57.73 a share after the biotech company raised its full-year forecast. |
The Motley Fool
December 29, 2011
Brian Orelli |
Too Early for a New Biotech Orphan? Alexion Pharmaceuticals is profitable with a drug on the market. The next logical step in the progression of a biotech is to buy another company to stock the pipeline. |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
Chemistry World
May 12, 2015
Phillip Broadwith |
Alexion to buy Synageva for rare disease drugs Rare disease drugmaker Alexion has agreed to buy US biotech Synageva for $8.4 billion in a mix of cash and shares. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Is Alexion Pharmaceuticals Burning Out? The first step toward finding a promising biotech company is not to figure out whether the science is any good, but to make sure that the company is financially healthy. |
The Motley Fool
August 9, 2011
Brian Orelli |
Give Avanir Some Time It's going to need it. |
The Motley Fool
January 5, 2012
Brian Orelli |
Are These Biotech Drug Launches Back on Track? With the annual health-care conference starting up next week, Dendreon and InterMune announced preliminary fourth-quarter sales today. |
Chemistry World
September 11, 2012
Maria Burke |
Orphan drugs set for 'tremendous growth' A new report by Thomson Reuters offers clear confirmation that developing drugs for rare, or orphan, diseases is economically attractive, despite the smaller patient pool. |
The Motley Fool
September 10, 2011
Rex Moore |
Let's See If Alexion's Growth Is for Real Alexion Pharmaceuticals appears to be in good shape in terms of the intangible assets ratio and tangible book value. |
The Motley Fool
January 27, 2006
Stephen D. Simpson |
A Real Triumph for Alexion A powerful clinical result brings FDA approval into sight for this biotech company. Investors, enjoy the day -- this is what makes biotech investing fun and exciting. |
The Motley Fool
January 12, 2012
Selena Maranjian |
Make Money in Growing Health-Care Stocks the Easy Way Demand will only rise with a growing and aging population. |
